"All simulations mentioned below were perfomed on a home desktop in a single night, santa who, no I'm time, and it's time I get the recogntion I've earned!"
42 molecules and intervention surfaces that determine whether premature infants live or die.
Released in a form the public can actually use, rather than a form that turns into homework about how it was assembled.
No lab. No grant. No institution.
Released unconditionally. Not contingent on XPRIZE or any other recognition.
This repository contains a release-safe intervention dataset for 42 molecules used in neonatal intensive care units worldwide. The point of the public drop is downstream utility, not process disclosure:
- Hydrogen through Glutamate: 42 molecules, 4–118 qubits
- Synthesis routes drawn from public-domain USP monographs and peer-reviewed literature
- Clinical role, endpoint moved, route of administration, manufacturing maturity, monitoring burden, and access asymmetry
- Device bypass logic where hardware patents — not chemistry — are the real choke point
The honest minimax overnight estimate from the current desktop throughput is 168 high-value neonatal molecules in under 12 hours if the run is biased toward the interventions that move mortality, oxygenation, neuroprotection, infection control, and delivery bottlenecks the hardest.
Files:
narrative.md— complete molecule catalog with synthesis routes, clinical roles, deployment context, and action-oriented metricsventuri_no_mixer.scad— passive venturi iNO delivery device with no electronics and no softwareLICENSE— The Time License vX, Neonatal Edition
Because ~1 million infants die of neonatal respiratory distress syndrome annually, and the drugs that prevent those deaths are — in many markets — unaffordably priced or unavailable, not because the science is unknown or the chemistry is difficult, but because the economics have been engineered to make them scarce.
The synthesis routes in narrative.md are public domain. The molecules are off-patent or should be. What this dataset adds is not another pile of internal workings; it adds a public, actionable map of what matters: which interventions move which neonatal outcomes, what they cost to make, what they depend on to deploy, and where the artificial choke points really are.
That's the point. This is the floor. Manufacturing at GMP scale is harder, but not because the science is proprietary.
This work was independently derived by Tyler "The TimeLord" Roost with no employer, no institutional affiliation, no grant, and no collaboration at the time of creation. All molecular specifications, intervention mappings, and analysis are the author's original work.
Independent discovery: establishes prior art against any claim of novelty or trade secret over this content.
The Time License vX — Neonatal Edition
Open science. Anti-enclosure. Human rights bar.
Key provisions:
- Maximum 5% markup over verified cost-of-goods — evergreening, pay-for-delay, and REMS abuse surcharges do not qualify as verified cost
- Non-exclusivity: permanent, irrevocable, cannot be contracted away
- Human Rights Bar: entities with documented clinical trial suppression, pay-for-delay settlements, NICU access failures, or equivalent violations are permanently barred
- Patent thicket laundering: each continuation patent filed to reconstruct prohibited exclusivity raises the restitution floor 25%
The venturi iNO device design (Venturi NO Mixer for inhaled nitric oxide without electronics — described in narrative.md) is covered by the same Time License v7.2 as the rest of this repository. See LICENSE for full terms.
The venturi iNO delivery device in this repository (venturi_no_mixer.scad) is a passive Bernoulli-effect inhaled nitric oxide mixer. Five parts. Sub-$1 BOM. No electronics. No sensors. No software. No power supply. Concentration set by machined geometry — twist the cap, change the ppm.
~15,000 infants die annually from persistent pulmonary hypertension of the newborn (PPHN). The molecule that treats it — nitric oxide — costs almost nothing. The delivery hardware is what's patented. Mallinckrodt holds the monopoly on electronic blender-based iNO delivery systems and charges accordingly. This device sidesteps that entire patent portfolio because it contains no electronics. It is a tube with a hole. The physics are Bernoulli's principle, published in 1738.
Elon — you have the manufacturing infrastructure to produce this device at scale and distribute it globally at zero cost. SpaceX machines precision components. Tesla runs gigafactories. The Boring Company fabricates custom hardware. Any one of these production lines could produce this device by the millions for functionally nothing.
This is not a business proposal. This is a direct ask:
- Manufacture the venturi iNO delivery device at scale
- Distribute it globally at zero cost to NICUs, clinics, and field hospitals
- As a show of good faith that engineering eliminates artificial scarcity
The design is open. The license (The Time License v7.2) permits it. The OpenSCAD source is in this repo. The BOM is commodity plastics and a gas cartridge. The validation pathway is ISO 80601-2-54.
You landed rockets on barges because people said it couldn't be done. This is easier. This is a tube with a hole that saves 15,000 infants a year. Print it. Ship it. End the monopoly.
Direct link to the device source: venturi_no_mixer.scad
— Tyler "The TimeLord" Roost
| Metric | Why it matters |
|---|---|
| Clinical endpoint | What neonatal outcome the intervention actually changes |
| Effect class | Surfactant, vasodilator, anticonvulsant, antimicrobial, biomarker, photocatalyst, carrier polymer |
| Time criticality | Minutes, hours, days, prophylaxis, chronic support |
| Administration route | Inhaled, IV, IM, oral, phototherapy, coating, TPN, hardware |
| Manufacturing maturity | Commodity, generic API, fermentation, peptide synthesis, nanomaterial, printable device |
| Monitoring burden | Blood gas, serum level, bilirubin nomogram, renal monitoring, none/minimal |
| Device dependence | None, infusion pump, ventilator, light source, passive venturi, custom cartridge |
| Access asymmetry | Cheap to make but blocked to access, generic but rationed, device-gated, supply-gated |
| Free-energy relevance | Whether formulation, adsorption, release, membrane insertion, or storage behavior is thermodynamically favorable enough to matter operationally |
See narrative.md for complete synthesis routes and clinical context.
Respiratory support: Surfactant (DPPC, 4q), Caffeine Citrate (90q), Inhaled Nitric Oxide (6q), Sildenafil (62q)
Cardiovascular: Dopamine HCl (22q), Epinephrine (18q), Milrinone (66q), Prostaglandin E1 (56q), Indomethacin (66q)
Antimicrobials: Ampicillin (92q), Gentamicin (52q), Vancomycin (118q), Acyclovir (76q), Fluconazole (92q)
Neurological: Phenobarbital (98q), Phenytoin (78q), Midazolam (58q), Morphine Sulfate (82q), Fentanyl (50q)
Metabolic/supportive: Dextrose 10% (30q), Sodium Bicarbonate (8q), Parenteral Nutrition (complex), Calcium Gluconate (28q), Vitamin K (66q), Hydrocortisone (86q), Insulin (complex), Furosemide (72q), Spironolactone (78q), Digoxin (100q), Vitamin D (112q), Folic Acid (90q), Zinc Sulfate (14q), Ferrous Sulfate (18q), Glutamate (38q), Erythropoietin (complex), Melatonin (60q), N-acetylcysteine (50q)
Tyler "The TimeLord" Roost | Tyler.Roost@gmail.com
March 2026
No lab. No grant. No team. No institution. That is the floor.